Evonik agrees to sell its Methacrylates business to Advent International for €3 billion

Essen, Germany. Evonik has today signed an agreement to sell its Methacrylates business to Advent International for €3 billion. The selling price (enterprise value) is 8.5 times the business’ EBITDA. The transaction is subject to approval by the authorities in several countries and is expected to close in the third quarter of this year.

New and Novel Excipients – Part 2

Existing and emerging mitigation strategies for the prevention of accidental overdose from oral pharmaceutical products Review

Design and Development of Dual Functional Colon Targeted Eudragit/Chitosan Nanoparticles: A QbD Approach

The Methacrylates business has 18 production sites and 3,900 employees worldwide. From 2016 to 2018, the business generated an average annual EBITDA of about €350 million and sales of about €1.8 billion per year. For 2019 Evonik expects sales and EBITDA at a similar level. Read the full press release here

What does this mean for the pharmaceutical excipient market?

excipients